{"name":"Alimentiv Inc.","slug":"alimentiv-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Treatment Algorithm A","genericName":"Treatment Algorithm A","slug":"treatment-algorithm-a","indication":"Other","status":"marketed"},{"name":"Treatment Algorithm C","genericName":"Treatment Algorithm C","slug":"treatment-algorithm-c","indication":"Other","status":"marketed"},{"name":"Treatment Algorithm B","genericName":"Treatment Algorithm B","slug":"treatment-algorithm-b","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Mirikizumab (MIR)","genericName":"Mirikizumab (MIR)","slug":"mirikizumab-mir","indication":"Ulcerative colitis","status":"marketed"}]}],"pipeline":[{"name":"Treatment Algorithm A","genericName":"Treatment Algorithm A","slug":"treatment-algorithm-a","phase":"marketed","mechanism":"Treatment Algorithm A is a clinical decision-support tool or protocol developed by Alimentiv Inc. for managing gastrointestinal or digestive conditions.","indications":[],"catalyst":""},{"name":"Treatment Algorithm C","genericName":"Treatment Algorithm C","slug":"treatment-algorithm-c","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Mirikizumab (MIR)","genericName":"Mirikizumab (MIR)","slug":"mirikizumab-mir","phase":"marketed","mechanism":"Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in immune-mediated diseases.","indications":["Ulcerative colitis","Crohn's disease"],"catalyst":""},{"name":"Treatment Algorithm B","genericName":"Treatment Algorithm B","slug":"treatment-algorithm-b","phase":"marketed","mechanism":"Treatment Algorithm B is a clinical decision-support tool or therapeutic protocol developed by Alimentiv Inc. for gastrointestinal or digestive disorders.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQOExnR01jLUlZamFMTVBrN3FjMFJidTc1LV96SHpjZjB6NFdKY2lldmE3U2FKTHl4ZjUxdEtfZTd3TVh3WEh1ZVdaaUxEREpicjVWWktQX3l4a0RrenFrQml2cHZZM1MtOU1MR2VvNHFBRTZHRHpiNV9yeVFteFpRb19UVmM3ZGxMcEdKdlVUZmFhUE42VXQ0SWp0ZUZ6N09fbi13WHc2SW1wc0ZnZ0s1emxabzZvM041NjNXLU5PMGExVlpZNGV1dUV4MW5NcDZ2SU1GenJfS2V4Q3I4aVF3OEZkZGx5R2xSYnpybkpXay1RV2lNeVIwVk0tTm5fWDBUQ0luU04yQWY0SjlRZlBLQXdLNVczZmxPNkRNVk1R?oc=5","date":"2025-05-01","type":"pipeline","source":"BioSpace","summary":"Alimentiv and Dova Health Intelligence (Previously Satisfai Health Inc.) Launch an AI Solution for Scoring of Ulcerative Colitis (UC) at DDW 2025 in San Diego - BioSpace","headline":"Alimentiv and Dova Health Intelligence (Previously Satisfai Health Inc.) Launch an AI Solution for Scoring of Ulcerative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNakVsQXFtQlpSQ1FSNDFIWUQ5WS1CbVdkSHQtVXpIZnlUQzlDVmRmem9jeFVFYlFUSFFnM0NiZ1hhTlVKN0pZeFBHTmlSUV85UUFHWmNoVDJLQXlzMmNQa3g1RVNlejFUaV8ycGN3a0RIdW9qWHBtSHBnZm9MbTZUUUFFNURCNGRGbjB6MnV0UXhnbGRGMjdHQmx0RnJ2VlJ1ZXF1ZS04UWc5VHlPY3ZRc2NIektNOWJ3b0ZoZzg1QzVwaFNEWEdfdDVQemljWEw2aDJpNEs1Zm11R2w2REpZLUtGb29hWVNFUDYySjNtYmtTd21HcnJZaw?oc=5","date":"2025-02-03","type":"trial","source":"PR Newswire","summary":"PhaseV and Alimentiv Partner on Machine Learning-Based Solution to Tackle Challenges in GI Clinical Trials - PR Newswire","headline":"PhaseV and Alimentiv Partner on Machine Learning-Based Solution to Tackle Challenges in GI Clinical Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxQWEM4MG1XU1BSRVdpZzhRZkNnUDdCTHNjR2l3RzB2c1AzbWdKQWcwMjlHNmcwX21OMjB0N1MyRTlpQ1FIWW5WbHA3dThGVmNuT01oVEJRYlNzTFhGWlkweGVSV0xYNXhxU1lJVTZ4emdQcmFVMVlTN21YWktoZ1MwSGQtVGlkV0xuaEZNQUdZVkRMZExST3hmZDktODBod0tBNVJYaGhqOVpLeTFTWkhweWZFRzcyekNpVV9WQXZPODJXdk5xeDFnRzUxbjg3QWVnNThqbnBFb1pKNXlGa0tqUUdfWjctMmcxU0N0MlhtVGFiOGNqR24zWjM4R1ZwaVEtcjNTbG91Vy1WeWRQUVNORHhnNA?oc=5","date":"2023-11-08","type":"trial","source":"PR Newswire","summary":"Alimentiv, AcelaBio, and PharmaNest Unite To Revolutionize Precision Medicine and AI Digital Pathology For NASH/MASH Clinical Trials. - PR Newswire","headline":"Alimentiv, AcelaBio, and PharmaNest Unite To Revolutionize Precision Medicine and AI Digital Pathology For NASH/MASH Cli","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOczN6a0VrMHJoMS1oXzFuZkJSMG5fcFNKVXhwOHJwbDRYeDdVdWVJeDRramZpdjYxS3lvZ09Rb3JNbG1jOW9DeUwxeHBwSVlFaXRTeTJCRTBHNDNjbW5Ua09pMXBFYW9DMDJoU1RscXhoWVNnSnh1Z2s5N1Z2bXNmcXNycGhqV3ZWRVFOaGU2eTNaaEJXc3Vsd3U1UlhuWXhTN0ZyeE16endVeXRIWS1iN1NZTGJjdTE5amhkZkk0ZnU4R1JXM0dNWUtBMkhmdGZ6cEVBcFd2TFhvUlR0?oc=5","date":"2023-10-13","type":"pipeline","source":"Newswire Canada","summary":"Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics - Newswire Canada","headline":"Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wJBVV95cUxQMXVXS2N3ZzEyMzA3Qlg2VDU4OGV4cnRzY2lUWjhNejJZdGhhMTdMTzNTLWN2NmUtLWZ0U0hSR2FTSmhzNm10bXRpYnJPQU1xMlpKWDNaTmpOS2hNNmNlZm96NEE2dE5Peks0ajZRVjE1TGxDQXhBRWZ1T2xyNHpZNDcxbDdVUTBsU1p3WWl4eVJaeThKanAySkFPUzJIemZPUWZFT1FuXzNGYkkyWEZ2UGRxZkRUU0VKd2hGUzVEb19xSzdlaGN5dHVKMGMtY2dXWmhGcHBsVWFTRWtnWjVWbHN4TjlnOFZ3RFBMQWxhazNnZ3dsbWpPdVhhaDdXRjdtYnUwcmIzNHV1N3doclRqZGtZMExZMUlBQ3FhWHlmaTN3V2dmODlqQnRUdjJmaGpmRFdKdkxYNXpEMmZiN1lOaWNLMzBuVDU1cmx5Qzd2VUhYejNSWGpSRENuaw?oc=5","date":"2023-10-10","type":"trial","source":"Newswire Canada","summary":"Alimentiv and Satisfai Health Announce Commercial Availability of Highly Innovative AI-Powered Scoring Tool for the Assessment of Ulcerative Colitis in Stage I through IV Clinical Trials - Newswire Ca","headline":"Alimentiv and Satisfai Health Announce Commercial Availability of Highly Innovative AI-Powered Scoring Tool for the Asse","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOcTVialNPQVZGYTRsU0duOFRGSHdQQmNFZ05pdkFjNE1rRnQ2d2VZaENiY2ZzYTQ3cUNWcExZMUdNeGNsQlNSN2FPUXIzX0Rob2w2ZHkwQUdhaUxhcmZwM0VXZ19XZGU3YXhQdFRoQ1NGRkVtSkhCV2hqZ2hzQzJMaUZoV1BIZmJpLXpNZWtUVFJ4QkRKWmVwbEZDRTRjSWlyVHlSazI1SjJXbzFWVVhlTTI5eXVvS1ZqeElhOEpkSUdZOFM4WVZTVmZkQQ?oc=5","date":"2022-11-23","type":"pipeline","source":"Healio","summary":"VEGA: Guselkumab plus golimumab achieved higher clinical remission rates in UC - Healio","headline":"VEGA: Guselkumab plus golimumab achieved higher clinical remission rates in UC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNemRXMXdubFhLX2ktWlhUUEtMNzRaQVA3djVjbWhsSVV2RFlqT2pVUWtfZWVHRkQ1Q1JVNE1PWUJNUjY4cmg2czN6R0VabjIxZFF4RWxqeHFxeUpQYk5YcmlCQjg2cnZReDFia3pxVjIwY1pEakhEbW5oZDdQMmpfRExOWHFONDZhVDZsY3hZeGJRdmkzWnV0TmJwZ1VKVng1akpqMXRqWEVGdnV0dUE4dXpHX25WODN5YUl2YmRtcDlTOFNjbGRnQTN3cUFGM21jVmc?oc=5","date":"2022-10-24","type":"pipeline","source":"Healio","summary":"Higher-dose upadacitinib reduces disease severity, prolongs clinical remission in UC - Healio","headline":"Higher-dose upadacitinib reduces disease severity, prolongs clinical remission in UC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxPaGwwSDJhQkFTX19RLWdpdXpiVUg1eWhpLXg0dEVQX1o4M1E2SFpvdmFYZUhhR3RXdlhVVVc2VmZfSV9Ub1hiQ3A1aXJLQnV1RTd5cVA5MVp3Nm0xYTFZUzhiMVlCa1BtV2szTDVRLWZVbm1oX0J3dmJGZVI0b2xkQTJKRVZmSnFIZVdUV0Z5UkQyaGFkYlBUd0h5YlplSjZVMUVVR1VNSWJ6MUU2c1JOdktsc0hTRnRjb2RnNTdEekg0cEVSSms2OHp1bHBVeHdmeU1Pb2pZMl9kOWFOY2t6dEs1WEUtam9BYV9zTk42blRCOG5iYk9HcGVrUXBGSVQ1SUZKV3hDTmdWMVZ4WEZzenJrNV9WeWJfYWo5UmhyU0hvaFFRaGZmSFBvUEFQR0pnNFdvRmN3MENVdUpWWHZkd2hIbk5td1VlbnFtWGJHLW1IT3VZUXc?oc=5","date":"2021-04-14","type":"trial","source":"Newswire Canada","summary":"Alimentiv Health Trust Launches AcelaBio (US) Inc. - A Commercial State-of-the-art Research Laboratory Delivering Histopathology And Precision Medicine Services For Global Clinical Trials - Newswire C","headline":"Alimentiv Health Trust Launches AcelaBio (US) Inc. - A Commercial State-of-the-art Research Laboratory Delivering Histop","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPZldmb3YzQ1hheV9FTE44UkM0eTVrRzhmTXJHdWhIbV9GWndwbmJVLWlYNjBXb3owRlFBQk1mdk5iMTUxdDRvMmEyU1QtTnRsRVlPbmtjekhLamJ2ZmJSS01rRU9ZQTdVT3oyYnFwUmJvTWhtSEtvaFY4ek4wcVNQMUVQcTBYeFhONHdXcERn?oc=5","date":"2021-03-02","type":"deal","source":"Contract Pharma","summary":"Alimentiv Acquires McDougall Scientific - Contract Pharma","headline":"Alimentiv Acquires McDougall Scientific","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":4},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}